{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T21:19:36Z","timestamp":1790803176846,"version":"4.1.0"},"reference-count":63,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ther Adv Respir Dis"],"published-print":{"date-parts":[[2019,1]]},"abstract":"<jats:p> Years of tremendous study have dawned a new era for the treatment of cystic fibrosis (CF). For years CF care was rooted in the management of organ dysfunction resulting from the mal-effects of absent anion transport through the CF transmembrane regulator (CFTR) protein. CFTR, an adenosine triphosphate binding anion channel, has multiple functions, but primarily regulates the movement of chloride anions, thiocyanate and bicarbonate across luminal cell membranes. Additional roles include effects on other electrolyte channels such as the epithelial sodium channel (ENaC) and on pulmonary innate immunity. <\/jats:p><jats:p> Inappropriate luminal anion movement leads to elevated sweat chloride concentrations, dehydrated airway surface liquid, overall viscous mucous production, and inspissated bile and pancreatic secretions. As a result, patients develop the well-known CF symptoms and disease-defining complications such as chronic cough, oily stools, recurrent pulmonary infections, bronchiectasis, chronic sinusitis and malnutrition. <\/jats:p><jats:p> Traditionally, CF has been symptomatically managed, but over the past 6 years those with CF have been offered a new mode of therapy; CFTR protein modulation. These medications affect the basic defect in CF: abnormal CFTR function. Ivacaftor, approved for use in the United States in 2012, is the first medication in CF history to improve CFTR function at the molecular level. Its study and approval were followed by two additional CFTR modulators, lumacaftor\/ivacaftor and tezacaftor\/ivacaftor. <\/jats:p><jats:p> To effectively use currently available CF therapies, clinicians should be familiar with the side effects of the drugs and their impacts on patient outcomes. As many new modulators are on the horizon, this information will equip providers to discuss the benefits and shortcomings of modulator therapy especially in the context of limited healthcare resources. <\/jats:p>","DOI":"10.1177\/1753466619844424","type":"journal-article","created":{"date-parts":[[2019,4,27]],"date-time":"2019-04-27T06:22:59Z","timestamp":1556346179000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":24,"title":["The combination of tezacaftor and ivacaftor in the treatment of patients with cystic fibrosis: clinical evidence and future prospects in cystic fibrosis therapy"],"prefix":"10.1177","volume":"13","author":[{"given":"Sherstin T.","family":"Lommatzsch","sequence":"first","affiliation":[{"name":"National Jewish Health, 1400 Jackson Street, J318, Denver, CO 80206, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer L.","family":"Taylor-Cousar","sequence":"additional","affiliation":[{"name":"National Jewish Health, 1400 Jackson Street, J318, Denver, CO 80206, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2019,4,26]]},"reference":[{"key":"bibr1-1753466619844424","unstructured":"Peckham D, Littlewood JM. A history of cystic fibrosis. www.cfmedicine.com (2011, accessed 18 June 2018)."},{"key":"bibr2-1753466619844424","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.1999.79.1.S3"},{"key":"bibr3-1753466619844424","volume-title":"Patient registry 2016 annual data report","author":"Cystic Fibrosis Foundation","year":"2017"},{"key":"bibr4-1753466619844424","doi-asserted-by":"publisher","DOI":"10.1001\/archpedi.1938.01980140114013"},{"key":"bibr5-1753466619844424","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1542\/peds.8.5.648","volume":"8","author":"Kessler WR","year":"1951","journal-title":"Pediatrics"},{"key":"bibr6-1753466619844424","doi-asserted-by":"publisher","DOI":"10.1097\/00000441-195301000-00011"},{"key":"bibr7-1753466619844424","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1542\/peds.12.5.549","volume":"12","author":"Di Sant\u2019agnese PA","year":"1953","journal-title":"Pediatrics"},{"key":"bibr8-1753466619844424","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1542\/peds.23.3.545","volume":"23","author":"Gibson LE","year":"1959","journal-title":"Pediatrics"},{"issue":"13","key":"bibr9-1753466619844424","first-page":"1","volume":"53","author":"Grosse S.","year":"2015","journal-title":"MMWR Recomm Rep"},{"key":"bibr10-1753466619844424","doi-asserted-by":"publisher","DOI":"10.1126\/science.2570460"},{"key":"bibr11-1753466619844424","unstructured":"cftr2.org. Accessed December 2018."},{"key":"bibr12-1753466619844424","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201204-0785PP"},{"key":"bibr13-1753466619844424","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(12)70057-7"},{"key":"bibr14-1753466619844424","volume-title":"2016 Annual data report","author":"Cystic Fibrosis Foundation Patient Registry","year":"2016"},{"key":"bibr15-1753466619844424","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-med-120611-144851"},{"key":"bibr16-1753466619844424","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMe1712335"},{"key":"bibr17-1753466619844424","unstructured":"Cystic Fibrosis Trust. Antibiotic treatment for cystic fibrosis. 3rd ed. Report of the UK Cystic Fibrosis Trust Antibiotic Working Group, 2009."},{"key":"bibr18-1753466619844424","doi-asserted-by":"publisher","DOI":"10.1038\/354526a0"},{"key":"bibr19-1753466619844424","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0904709106"},{"key":"bibr20-1753466619844424","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1105185"},{"key":"bibr21-1753466619844424","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201301-0153OC"},{"key":"bibr22-1753466619844424","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2014.09.005"},{"key":"bibr23-1753466619844424","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(15)00201-5"},{"key":"bibr24-1753466619844424","doi-asserted-by":"publisher","DOI":"10.1378\/chest.11-2672"},{"key":"bibr25-1753466619844424","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709846"},{"key":"bibr26-1753466619844424","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709847"},{"key":"bibr27-1753466619844424","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1409547"},{"key":"bibr28-1753466619844424","volume":"193","author":"Drew L","year":"2016","journal-title":"C60 All About Cystic Fibrosis"},{"key":"bibr29-1753466619844424","volume":"181","author":"Farrell PM","year":"2017","journal-title":"J Pediatr"},{"key":"bibr30-1753466619844424","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201503-0578OC"},{"key":"bibr31-1753466619844424","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(16)30427-1"},{"key":"bibr32-1753466619844424","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0909825"},{"key":"bibr33-1753466619844424","unstructured":"KALYDECOTM. Kalydeco (ivacaftor) [package insert]. Cambridge, MA: Vertex Pharmaceutical Inc. 2012."},{"key":"bibr34-1753466619844424","doi-asserted-by":"publisher","DOI":"10.1378\/chest.08-1190"},{"key":"bibr35-1753466619844424","unstructured":"Orkambi (lumacaftor\/ivacaftor) [package insert]. Boston, MA: Vertex Pharmaceuticals Inc. 2016."},{"key":"bibr36-1753466619844424","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1409547"},{"key":"bibr37-1753466619844424","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00159111"},{"key":"bibr38-1753466619844424","volume":"18","author":"Bratcher PE","year":"2018","journal-title":"J Cyst Fibros"},{"key":"bibr39-1753466619844424","doi-asserted-by":"publisher","DOI":"10.1378\/chest.12-1430"},{"key":"bibr40-1753466619844424","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(14)70132-8"},{"key":"bibr41-1753466619844424","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201608-1754OC"},{"key":"bibr42-1753466619844424","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(17)30215-1"},{"key":"bibr43-1753466619844424","volume":"51","author":"Sagel SD","year":"2016","journal-title":"Pediatr Pulmonol"},{"key":"bibr44-1753466619844424","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2017.09.012"},{"key":"bibr45-1753466619844424","unstructured":"Symdeko (tezacaftor\/ivacaftor) [package insert]. Boston, MA: Vertex Pharmaceuticals Inc. 2018."},{"key":"bibr46-1753466619844424","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2018.05.009"},{"key":"bibr47-1753466619844424","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2017-210394"},{"key":"bibr48-1753466619844424","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2017.09.012"},{"key":"bibr49-1753466619844424","unstructured":"Symdeko (tezacaftor\/ivacaftor and ivacaftor) Initiation Guide. Boston, MA: Vertex Pharmaceuticals Incorporated, 2018."},{"key":"bibr50-1753466619844424","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201710-1983OC"},{"key":"bibr51-1753466619844424","doi-asserted-by":"publisher","DOI":"10.1016\/j.healthpol.2014.12.016"},{"key":"bibr52-1753466619844424","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201507-1428ED"},{"key":"bibr53-1753466619844424","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.11237"},{"key":"bibr54-1753466619844424","doi-asserted-by":"publisher","DOI":"10.1093\/qjmed\/hci128"},{"key":"bibr55-1753466619844424","volume-title":"Final Evidence Report and Meeting Summary","author":"Balk E"},{"key":"bibr56-1753466619844424","doi-asserted-by":"publisher","DOI":"10.2217\/cer.14.34"},{"key":"bibr57-1753466619844424","unstructured":"Elborn S, Elston C, Haworth CS. Letter from CFPMG to Simon Stevens NHS England. In: Stevens S, Executive C, England NHS (eds) Cystic Fibrosis Trust, 2018."},{"key":"bibr58-1753466619844424","unstructured":"The availability of Orkambi\u00ae (containing lumacaftor and ivacaftor) through the Pharmaceutical Benefits Scheme for patients with cystic fibrosis. Australian Government Department of Health, 2018."},{"key":"bibr59-1753466619844424","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(15)00507-X"},{"key":"bibr60-1753466619844424","unstructured":"Proteostasis announces positive data from ongoing phase 1 study of PTI-801 in cystic fibrosis patients on background Orkambi\u00ae therapy. Proteostasis Therapeutics, Inc., 2018. http:\/\/ir.proteostasis.com\/news-releases\/newsrelease-details\/proteostasis-announces-positive-dataongoing-phase-1-study-pti"},{"key":"bibr61-1753466619844424","volume-title":"Drug development","author":"Cystic Fibrosis Foundation","year":"2018"},{"key":"bibr62-1753466619844424","doi-asserted-by":"crossref","unstructured":"Lancastre J. CRISPR\/Cas9 approach for cystic fibrosis treatment. Cystic Fibrosis News Today January 16, 2017. https:\/\/cysticfibrosisnewstoday.com\/crisprcas9-approach-forcystic-fibrosis\/","DOI":"10.1016\/j.jcf.2017.03.009"},{"key":"bibr63-1753466619844424","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2017.02.012"}],"container-title":["Therapeutic Advances in Respiratory Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1753466619844424","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1753466619844424","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1753466619844424","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,2]],"date-time":"2025-03-02T17:15:07Z","timestamp":1740935707000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1753466619844424"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":63,"alternative-id":["10.1177\/1753466619844424"],"URL":"https:\/\/doi.org\/10.1177\/1753466619844424","relation":{},"ISSN":["1753-4666","1753-4666"],"issn-type":[{"value":"1753-4666","type":"print"},{"value":"1753-4666","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1]]},"article-number":"1753466619844424"}}